A combination of two monoclonal antibodies, casirivimab and imdevimab, has received emergency use authorization for the treatment of mild to moderate COVID-19.Casirivimab and imdevimab come in separate packages but must be combined into one IV infusion after dilution.
Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19.